Silencing hepatic PCSK9 via novel chimeric AAV8 mitigates the progression of atherosclerosis by inhibiting inflammation in ApoE^-/- mice.

Notably, a 50% decrease in hepatic PCSK9 protein levels led to a 59.4% reduction in circulating ApoB levels after 4 weeks ( Figure 3 E), along with a decreasing trend in hepatic ApoB and Apolipoprotein E (ApoE) protein expression, although this trend did not achieve statistical significance ( Figures 3 F and 3G).

also in 47,180 other papers